TREMFYA™ (guselkumab)
AXERT® (almotriptan malate) Tablets
CONCERTA® (methylphenidate HCI) Extended-release Tablets CII
DARZALEX® (daratumumab)
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA SUSTENNA®
INVEGA TRINZA® (paliperidone palmitate) extended-release injectable suspension 273 mg, 410 mg, 546 mg, or 819 mg
INVEGA TRINZA®
INVOKAMET® (canagliflozin/metformin HCl) tablets
INVOKAMET® XR (canagliflozin/metformin HCl extended-release) tablets
INVOKAMET® XR
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
OLYSIO® (simeprevir)
ORTHO TRI-CYCLEN® Lo (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® Lo
PANCREAZE® (pancrelipase) Delayed-Release Capsules
PREZCOBIX® (darunavir 800 mg/ cobicistat 150 mg) tablets
PREZISTA® (darunavir) tablets
PROCRIT® (epoetin alfa)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab)
SIMPONI ARIA®
SPORANOX® (itraconazole)
STELARA® (ustekinumab)
SYLVANT® (siltuximab)
TOPAMAX® (topiramate) Tablets
TREMFYA™ (guselkumab)
XARELTO® (rivaroxaban)
YONDELIS® (trabectedin)
ZYTIGA® (abiraterone acetate)

Need help paying for your TREMFYA™ (guselkumab) prescription?

We want to guide you to programs that may help. Here you'll find the financial assistance programs available for TREMFYA™. We have also listed most of the eligibility requirements for each, so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their websites to learn more.

Janssen CarePath

877-CarePath

(877-227-3728)

Monday-Friday, 8 AM to 8 PM ET

To view programs that are best suited for you, select your insurance status for TREMFYA™ or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for TREMFYA™ or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

The following programs are affiliated with Janssen.

They are updated on a regular basis. Be sure to visit the program site for additional information.

Janssen CarePath Savings Program for TREMFYA™

If you are eligible, you may be able to lower your out-of-pocket costs for TREMFYA™, including deductible, co-pay, and co-insurance medication costs. With Janssen CarePath Savings Program for TREMFYA™, eligible patients with commercial insurance pay just $5 per injection, with a $20,000 maximum program benefit each calendar year. Patients using Medicare, Medicaid, or any other federally funded programs to pay for TREMFYA™ are not eligible to participate in the program. Before the calendar year ends, you will receive information and eligibility requirements for continued participation in the program. There is no income requirement.

Click here for full eligibility requirements

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Savings Program

Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and co-insurance.

Find out if your state has a program that can help you »

Medicare Part D Extra Help — Low-Income Subsidy

Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.

Those who are eligible for LIS may:

  • Receive assistance paying their monthly premium
  • Have a reduced or no deductible
  • Have reduced or no prescription co-insurance and co-payments
  • Have no gap in coverage

Independent co-pay assistance foundations

Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse or show financial preference for any particular foundation. The foundations on this list are not the only ones that might be able to help you.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) provides free prescription medications to eligible individuals without insurance coverage for their medications and those who do not have adequate financial resources to pay for them. To see if you might qualify for assistance, please contact a JJPAF program specialist at 1-800-652-6227, (9 AM to 6 PM ET) or visit the foundation website at www.JJPAF.org.

August 22, 2017
Expand
Expand

IMPORTANT SAFETY INFORMATION

WHAT IS TREMFYA™ (guselkumab)?

TREMFYA™ is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).

What is the most important information I should know about TREMFYA™?

TREMFYA™ may cause serious side effects, including infections. TREMFYA™ is a prescription medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA™ and may treat you for TB before you begin treatment with TREMFYA™ if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA™.

Before using TREMFYA™, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYA™?

TREMFYA™ may cause serious side effects. See "What is the most important information I should know about TREMFYA™?"

The most common side effects of TREMFYA™ include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, and herpes simplex infections.

These are not all the possible side effects of TREMFYA™. Call your doctor for medical advice about side effects.

Use TREMFYA™ exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information and Medication Guide for TREMFYA™, and discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

075142-170622

IMPORTANT SAFETY INFORMATION

WHAT IS TREMFYA™ (guselkumab)?

TREMFYA™ is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).

What is the most important information I should know about TREMFYA™?

TREMFYA™ may cause serious side effects, including infections. TREMFYA™ is a prescription medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA™ and may treat you for TB before you begin treatment with TREMFYA™ if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA™.

Before using TREMFYA™, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYA™?

TREMFYA™ may cause serious side effects. See "What is the most important information I should know about TREMFYA™?"

The most common side effects of TREMFYA™ include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, and herpes simplex infections.

These are not all the possible side effects of TREMFYA™. Call your doctor for medical advice about side effects.

Use TREMFYA™ exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information and Medication Guide for TREMFYA™, and discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

075142-170622